Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany

Health Policy

Volumn 118, Issue 2, 2014, Pages 242-254

  Ruof, Jörg ^a,b   Knoerzer, Dietrich ^a   Dünne, Anja Alexandra ^a   Dintsios, Charalabos Markos ^c,d   Staab, Thomas ^a   Schwartz, Friedrich Wilhelm ^b  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c VFA DIE FORSCHENDEN PHARMA UNTERNEHMEN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

(Early) benefit assessment; Health related quality of life; Morbidity; Mortality; Oncology; Patient relevant endpoints

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABIRATERONE ACETATE; AFATINIB; AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BOSUTINIB; BRENTUXIMAB VEDOTIN; CABAZITAXEL; CRIZOTINIB; DABRAFENIB; ENZALUTAMIDE; ERIBULIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IPILIMUMAB; PERTUZUMAB; PIXANTRONE; POMALIDOMIDE; PONATINIB; REGORAFENIB; RUXOLITINIB; VANDETANIB; VEMURAFENIB; VISMODEGIB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BASAL CELL CARCINOMA; BENEFIT ASSESSMENT; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMMERCIAL PHENOMENA; DECISION MAKING; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MARKETING; EUROPEAN MEDICINES AGENCY; EVENT FREE SURVIVAL; GERMANY; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; MARKETING AUTHORISATION; MELANOMA; MORBIDITY; MORTALITY; MYELOID LEUKEMIA; MYELOMA; MYELOPROLIFERATIVE DISORDER; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; ONCOLOGY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; THYROID TUMOR; TREATMENT INDICATION; COMPARATIVE STUDY; DRUG APPROVAL; NEOPLASMS; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; GERMANY; HUMANS; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84922576703     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2014.08.004     Document Type: Article

References (24)

1. Bundesministerium für Gesundheit [AM-NutzenV] 2010, http://www.gesetze-im-internet.de/bundesrecht/am-nutzenv/gesamt.pdf [accessed June 2014].
2. IQWiG General methods 4.1 2013, https://www.iqwig.de/download/IQWiG_General_Methods_Version_%204-1.pdf [accessed June 2014].
3. G-BA Chapter 5: Assessment of the benefits of pharmaceuticals according to §35a SGB V 2012, http://www.english.g-ba.de/downloads/17-98-3042/2011-05-18_5%20Kapitel%20VerfO%20Englisch.pdf [accessed June 2014].
4. German Bundestag [Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477, letzte Änderung durch Artikel 3 des Gesetzes vom 20. Dezember 2012 (BGBI. I S. 2781))] 1988, http://www.gesetze-im-internet.de/bundesrecht/sgb_5/gesamt.pdf [accessed June 2014].
5. Hörn H., Nink K., McGauran N., Wieseler B. Early benefit assessment of new drugs in Germany - results from 2011 to 2012. Health Policy (Amsterdam, Netherlands) 2014, 116:147-153.
6. Ruof J., Schwartz F.W., Schulenburg J.M., Dintsios C.M. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation. European Journal of Health Economics 2014, 15:577-589.
7. Dabisch I., Dethling J., Dintsios C.M., Drechsler M., Kalanovic D., Kaskel P., et al. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany. Health Economics Review 2014, 4:2-9.
8. European Medicines Agency Guideline on the evaluation of anticancer medicinal products in man 2013, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf [accessed June 2014].
9. Food and Drug Administration Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics 2007, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf [accessed June 2014].
10. Enzmann H., Broich K. [Cancer: is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency]. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2013, 107:120-128.
11. G-BA Overview of products [Übersicht der Wirkstoffe] 2014, http://www.g-ba.de/informationen/nutzenbewertung/ [accessed June 2014].
12. Ruof J., Dintsios C.-M., Knoerzer D., Schwartz Questioning patient subgroups for benefit assessment: challenging the German G-BA approach. Value in Health 2014, 17:307-309.
13. Bezjak A., Tu D., Seymour L., Clark G., Trajkovic A., Zukin M., et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology 2006, 24:3831-3837.
14. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993, 85:365-376.
15. Soria J.C., Massard C., Le C.T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy. Annals of Oncology 2010, 21:2324-2332.
16. Wörmann B., Freund M., Overkamp F., Ehninger G. [Status of clinical trials in oncology - 2013 and onwards]. Onkologie 2013, 36(Suppl. 2):3-8.
17. Burzykowski T., Buyse M., Piccart-Gebhart M.J., Sledge G., Carmichael J., Luck H.J., et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology 2008, 26:1987-1992.
18. EUnetHTA Guideline - endpoints used for relative effectiveness assessment of pharmaceuticals: surrogate endpoints 2013, http://eunethta.fedimbo.belgium.be/sites/5026.fedimbo.belgium.be/files/Surrogate%20Endpoints.pdf [accessed June 2014].
19. National Institute for Health and Care Excellence Published technology appraisals 2013, http://guidance.nice.org.uk/TA/Published [accessed June 2014].
20. Haute autorité de santé Avis de Commission de la Transparence - Zelboraf 2012, http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/zelboraf_03102012_avis_ct12121.pdf [accessed June 2014].
21. Mangiapane S., Velasco G.M. Use of surrogate end points in HTA. GMS Health Technology Assessment 2009, 91. [HTA-Bericht].
22. EUnetHTA Guideline - endpoints used for relative effectiveness assessment of pharmaceuticals: clinical endpoints 2013, http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Clinical%20endpoints.pdf [accessed June 2014].
23. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993, 11:570-579.
24. King M.T., Cella D., Osoba D., Stockler M., Eton D., Thompson J., et al. Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Related Outcome Measures 2010, 1:119-126.